Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy

First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results

Swiss Med Wkly.

Murer C, Huber LC, Kurowski T, Hirt A, Robinson CA, Bürgi U, Benden C

doi: 10.4414/smw.2018.14593.

RECOMMENDED

Pulmonary Fibrosis

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study

Lancet Respir Med.

McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS

doi: 10.1016/S2213-2600(18)30460-0.

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Lancet Respir Med.

Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group

doi: 10.1016/S2213-

Pulmonary Fibrosis

Effects of Lumacaftor/Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis

Am J Respir Crit Care Med.

Graeber SY, Dopfer C, Naehrlich L, Gyulumyan L, Scheuermann H, Hirtz S, Wege S, Mairbäurl H, Dorda M, Hyde R, Bagheri-Hanson A, Rueckes-Nilges C, Fischer S, Mall MA, Tümmler B

doi: 10.1164/

Pulmonary Fibrosis

Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment

J Cyst Fibros.

Nagy B Jr, Bene Z, Fejes Z, Heltshe SL, Reid D, Ronan NJ, McCarthy Y, Smith D, Nagy A, Joseloff E, Balla G, Kappelmayer J, Macek M Jr, Bell SC, Plant BJ, Amaral MD, Balogh I

doi: 10.1016/j.jcf.2018.08.013.

Pulmonary Fibrosis

Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

N Engl J Med.

Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS

doi: 10.1056/

Pulmonary Fibrosis

Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients

Pediatr Pulmonol.

Bruch BA, Singh SB, Ramsey LJ, Starner TD

doi: 10.1002/ppul.24024.

Pulmonary Fibrosis

Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

N Engl J Med.

Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC

doi: 10.1056/

RECOMMENDED

Pulmonary Fibrosis

Non-invasive ventilation versus oxygen therapy in cystic fibrosis: A 12-month randomized trial

Respirology.

Milross MA, Piper AJ, Dwyer TJ, Wong K, Bell SC, Bye PTP, Non-Invasive Ventilation in Cystic Fibrosis (NIVCF) Study Group.

doi: 10.1111/resp.13604.

Related content

First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Effects of Lumacaftor/Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis

Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment

Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients

Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Non-invasive ventilation versus oxygen therapy in cystic fibrosis: A 12-month randomized trial